• Molecular NamePrimaquine
  • SynonymNA
  • Weight259.353
  • Drugbank_IDDB01087
  • ACS_NO90-34-6
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.33
  • pka10.3
  • LogD (pH=7, predicted)-0.62
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.23
  • LogSw (predicted, AB/LogsW2.0)0.94
  • Sw (mg/ml) (predicted, ACD/Labs)0.29
  • No.of HBond Donors3
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds6
  • TPSA60.17
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA medication used in the treatment of malaria and Pneumocystis pneumonia. It is a member of the 8-aminoquinoline group of drugs that includes tafenoquine and pamaquine.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability77.0
  • Protein binding75.0
  • Volume of distribution (VD)3 to 4 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic; Rapidly converted to carboxyprimaquine.
  • Half life5.8 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityGastrointestinal side effects: nausea; vomiting; epigastric distress; abdominal cramps. Hematologic side effects: leukopenia; hemolytic anemia in G-6-PD deficiency; methemoglobinemia in NADH methemoglobin reductase deficiency.
  • LD50 (rat)LD50=244 (female); LD50=177 (male)
  • LD50 (mouse)N/A